Vaccine induced antibody effector functions

Vaccine induced antibody effector functions

Traditionally, vaccine development has been a slow process, often taking a decade or more to develop, test, and license a new vaccine. Given the ongoing impact of the SARS CoV2 pandemic, the development cycle of SARS CoV2 vaccine has been rapidly accelerated, and the speed at which potential SARS CoV2 vaccines are being developed is unprecedented. However, working on an accelerated product development timeline necessitates changing the traditional approach to vaccine design.


Importantly, an accelerated timeline precludes a sequential approach to data acquisition as we no longer have the luxury of performing analyses to fully understand vaccine candidates after early trials are completed before larger efficacy trials begin and we no longer have time to complete post-hoc studies after adverse events are reported. Therefore, there is an urgent need to more deeply characterize candidate vaccines earlier in the development cycle, including identification of potential immunologic correlates of protection. While the generation of neutralizing antibodies remains the primary focus of all current vaccine candidates, an increasing number of SARS CoV2 vaccine developers are working with SeromYx to begin to evaluate extra-neutralizing activities to better define the total landscape of functions elicited by their antibodies generated by their vaccines.

Illustration of DNA vaccine Protection against SARS CoV2 Virus

Reference:

Yu J, et al., DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science.
2020. PMID: 32434945

updated: 3 days ago